Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age
- PMID: 23345574
- PMCID: PMC3711493
- DOI: 10.1136/thoraxjnl-2012-202342
Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age
Abstract
Background: Newborn screening allows novel treatments for cystic fibrosis (CF) to be trialled in early childhood before irreversible lung injury occurs. As respiratory exacerbations are a potential trial outcome variable, we determined their rate, duration and clinical features in preschool children with CF; and whether they were associated with growth, lung structure and function at age 5 years.
Methods: Respiratory exacerbations were recorded prospectively in Australasian CF Bronchoalveolar Lavage trial subjects from enrolment after newborn screening to age 5 years, when all participants underwent clinical assessment, chest CT scans and spirometry.
Results: 168 children (88 boys) experienced 2080 exacerbations, at an average rate of 3.66 exacerbations per person-year; 80.1% were community managed and 19.9% required hospital admission. There was an average increase in exacerbation rate of 9% (95% CI 4% to 14%; p<0.001) per year of age. Exacerbation rate differed by site (p<0.001) and was 26% lower (95% CI 12% to 38%) in children receiving 12 months of prophylactic antibiotics. The rate of exacerbations in the first 2 years was associated with reduced forced expiratory volume in 1 s z scores. Ever having a hospital-managed exacerbation was associated with bronchiectasis (OR 2.67, 95% CI 1.13 to 6.31) in chest CT scans, and lower weight z scores at 5 years of age (coefficient -0.39, 95% CI -0.74 to -0.05).
Conclusions: Respiratory exacerbations in young children are markers for progressive CF lung disease and are potential trial outcome measures for novel treatments in this age group.
Keywords: Bronchiectasis; Cystic Fibrosis; Respiratory Infection.
Figures



Similar articles
-
Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial.JAMA. 2011 Jul 13;306(2):163-71. doi: 10.1001/jama.2011.954. JAMA. 2011. PMID: 21750293 Clinical Trial.
-
Bronchiectases at early chest computed tomography in children with cystic fibrosis are associated with increased risk of subsequent pulmonary exacerbations and chronic pseudomonas infection.J Cyst Fibros. 2014 Sep;13(5):564-71. doi: 10.1016/j.jcf.2014.03.006. Epub 2014 Apr 13. J Cyst Fibros. 2014. PMID: 24726420
-
Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.Contemp Clin Trials. 2013 Nov;36(2):460-9. doi: 10.1016/j.cct.2013.09.004. Epub 2013 Sep 19. Contemp Clin Trials. 2013. PMID: 24055998 Free PMC article. Clinical Trial.
-
Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis.Thorax. 2021 Dec;76(12):1255-1265. doi: 10.1136/thoraxjnl-2020-216085. Epub 2021 Apr 29. Thorax. 2021. PMID: 33927017 Review.
-
Digital technology for early identification of exacerbations in people with cystic fibrosis.Cochrane Database Syst Rev. 2023 Apr 14;4(4):CD014606. doi: 10.1002/14651858.CD014606.pub2. Cochrane Database Syst Rev. 2023. PMID: 37057835 Free PMC article.
Cited by
-
Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging.Front Pediatr. 2023 Feb 6;10:1084313. doi: 10.3389/fped.2022.1084313. eCollection 2022. Front Pediatr. 2023. PMID: 36814432 Free PMC article. Review.
-
IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.J Cyst Fibros. 2016 May;15(3):372-9. doi: 10.1016/j.jcf.2015.10.006. Epub 2015 Oct 23. J Cyst Fibros. 2016. PMID: 26603642 Free PMC article.
-
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.Cochrane Database Syst Rev. 2022 Aug 1;8(8):CD008319. doi: 10.1002/14651858.CD008319.pub4. Cochrane Database Syst Rev. 2022. PMID: 35914011 Free PMC article.
-
State-of-the-art review of lung imaging in cystic fibrosis with recommendations for pulmonologists and radiologists from the "iMAging managEment of cySTic fibROsis" (MAESTRO) consortium.Eur Respir Rev. 2022 Mar 23;31(163):210173. doi: 10.1183/16000617.0173-2021. Print 2022 Mar 31. Eur Respir Rev. 2022. PMID: 35321929 Free PMC article.
-
Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis.Thorax. 2024 Sep 18;79(10):915-924. doi: 10.1136/thorax-2023-220559. Thorax. 2024. PMID: 38719441 Free PMC article.
References
-
- Sanders DB, Bittner RCL, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;46:393–400 - PubMed
-
- Britto M, Kotagal U, Hornung R, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64–72 - PubMed
-
- de Boer K, Vandemheen KL, Tullis E, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011;66:680–5 - PubMed
-
- Cystic Fibrosis Foundation . Clinical Practice Guidelines for Cystic Fibrosis. Bethesda, MD: Cystic Fibrosis Foundation, 1997
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials